Ankur Singla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ankur Singla has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Adishwar Rao
Department of Internal Medicine, Guthrie Robert Packer Hospital, Sayre, PA 18840, USA
1 shared publication - Aditi Bansal
Department of Obstetrics and Gynecology, Zanana Hospital, SMS Medical College and Hospital, Jaipur, India
1 shared publication - Ahmed Al-Kaisey
Department of Cardiology, Royal Melbourne Hospital , Level 2, 300 Grattan Street, Melbourne, VIC 3050 , Australia
1 shared publication Ahmed G. Zedan
Department of Cardiac Electrophysiology McGovern Medical School University of Texas Health Science Center at Houston Houston Texas USA
1 shared publication- Ahmed Sermed Al Sakini
College of Medicine University of Baghdad Baghdad Iraq
1 shared publication - Alejandro Vidal Margenat
Department of Cardiac Electrophysiology McGovern Medical School University of Texas Health Science Center at Houston Houston Texas USA
1 shared publication
Latest Publications
- 18 June 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Selective Cardioneuroablation for Symptomatic Sinus Bradycardia After Bariatric Surgery: A Report on two Cases
Functional bradycardia, characterized by a heart rate below the normal range due to dysregulation of the autonomic nervous system (ANS), poses a clinical challenge with limited treatment options. Symptomatic sinus bradycardia is an uncommon but potentially significant complication following bariatric surgery. Cardioneuroablation (CNA) has emerged as a novel therapeutic intervention targeting the cardiac ANS to modulate heart rate. This case series describes two patients, with the aim of providing a simplified but successful approach with targeted partial CNA for sinus bradycardia complicating bariatric surgery.
- 18 June 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Selective Cardioneuroablation for Symptomatic Sinus Bradycardia After Bariatric Surgery: A Report on two Cases
Functional bradycardia, characterized by a heart rate below the normal range due to dysregulation of the autonomic nervous system (ANS), poses a clinical challenge with limited treatment options. Symptomatic sinus bradycardia is an uncommon but potentially significant complication following bariatric surgery. Cardioneuroablation (CNA) has emerged as a novel therapeutic intervention targeting the cardiac ANS to modulate heart rate. This case series describes two patients, with the aim of providing a simplified but successful approach with targeted partial CNA for sinus bradycardia complicating bariatric surgery.
- 28 January 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (4) , 733-739
Ventricular Tachycardia Ablation Outcomes in Patients With Previous Implantable Cardioverter‐Defibrillator Insertion: A Multicenter Cohort Study
Background: Catheter ablation is increasingly used in patients with ventricular tachycardia (VT) and an implantable cardioverter‐defibrillator (ICD) device in situ, but its real‐world safety and effectiveness remain underexplored in this high‐risk population. We aim to evaluate in‐hospital outcomes associated with catheter ablation in VT patients with a history of ICD implantation using a large, nationally representative dataset. Methods: We performed a retrospective cohort study using the National Inpatient Sample (2016–2021) to identify adult hospitalizations with VT and prior ICD device insertion. Patients were stratified into ablation and non‐ablation groups. Propensity score matching was used to balance baseline characteristics. Primary outcome was in‐hospital mortality; secondary outcomes included acute heart failure, ST‐elevation myocardial infarction (STEMI), sepsis, major adverse cardiac events (MACE), and procedure‐related complications. Results: Among 395,290 hospitalizations with VT and prior ICD, 4.9% underwent ablation. Catheter ablation remained independently associated with reduced in‐hospital mortality (adjusted odds ratio [aOR] = 0.59; 95% CI: 0.48–0.74), acute heart failure (aOR = 0.59; 95% CI: 0.54–0.64), ST‐elevation MI (aOR = 0.44; 95% CI: 0.36–0.54), and sepsis (aOR = 0.34; 95% CI: 0.26–0.45) (all p < 0.001). The composite MACE outcome also showed a reduced odds ratio for ablation (aOR = 0.76; 95% CI: 0.68–0.85; p < 0.001). However, ablation was also associated with higher odds of cardiac tamponade (aOR = 8.33; 95% CI: 5.92–11.73), cardiogenic shock (aOR = 1.36; 95% CI: 1.19–1.55), need for mechanical circulatory support (aOR = 5.36; 95% CI: 4.63–6.21), and prolonged hospital stay ≥ 7 days (aOR = 1.69; 95% CI: 1.57–1.82) (all p < 0.001). Conclusion: In patients with VT and prior ICD implantation, catheter ablation is associated with improved in‐hospital outcomes but higher procedural risks. These findings support its selective use in experienced centers capable of managing complications.
- 28 January 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (4) , 733-739
Ventricular Tachycardia Ablation Outcomes in Patients With Previous Implantable Cardioverter‐Defibrillator Insertion: A Multicenter Cohort Study
Background: Catheter ablation is increasingly used in patients with ventricular tachycardia (VT) and an implantable cardioverter‐defibrillator (ICD) device in situ, but its real‐world safety and effectiveness remain underexplored in this high‐risk population. We aim to evaluate in‐hospital outcomes associated with catheter ablation in VT patients with a history of ICD implantation using a large, nationally representative dataset. Methods: We performed a retrospective cohort study using the National Inpatient Sample (2016–2021) to identify adult hospitalizations with VT and prior ICD device insertion. Patients were stratified into ablation and non‐ablation groups. Propensity score matching was used to balance baseline characteristics. Primary outcome was in‐hospital mortality; secondary outcomes included acute heart failure, ST‐elevation myocardial infarction (STEMI), sepsis, major adverse cardiac events (MACE), and procedure‐related complications. Results: Among 395,290 hospitalizations with VT and prior ICD, 4.9% underwent ablation. Catheter ablation remained independently associated with reduced in‐hospital mortality (adjusted odds ratio [aOR] = 0.59; 95% CI: 0.48–0.74), acute heart failure (aOR = 0.59; 95% CI: 0.54–0.64), ST‐elevation MI (aOR = 0.44; 95% CI: 0.36–0.54), and sepsis (aOR = 0.34; 95% CI: 0.26–0.45) (all p < 0.001). The composite MACE outcome also showed a reduced odds ratio for ablation (aOR = 0.76; 95% CI: 0.68–0.85; p < 0.001). However, ablation was also associated with higher odds of cardiac tamponade (aOR = 8.33; 95% CI: 5.92–11.73), cardiogenic shock (aOR = 1.36; 95% CI: 1.19–1.55), need for mechanical circulatory support (aOR = 5.36; 95% CI: 4.63–6.21), and prolonged hospital stay ≥ 7 days (aOR = 1.69; 95% CI: 1.57–1.82) (all p < 0.001). Conclusion: In patients with VT and prior ICD implantation, catheter ablation is associated with improved in‐hospital outcomes but higher procedural risks. These findings support its selective use in experienced centers capable of managing complications.
- 13 August 2025
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1) , 1-11
LADA: The Evolving Landscape of Adult-Onset Autoimmune Diabetes
- 13 August 2025
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1) , 1-11
LADA: The Evolving Landscape of Adult-Onset Autoimmune Diabetes
- Open Access
- 15 January 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-6
Shorter antitubercular therapy for extrapulmonary tuberculosis - a case report
Introduction: Extrapulmonary tuberculosis (EPTB) adds to India’s significant economic burden, with pericardial effusion being a potentially fatal complication. This case report highlights the need for early diagnosis and the feasibility of shorter-duration treatment for EPTB in developing countries. Presentation: This case report describes a 19-year-old male from Southeast Asia who had a history of bronchiectasis involving the left lower lobe and the right middle lobe, which was cystic in nature, as well as multiple episodes of non-tuberculous pneumonia. Currently, he presented with fever, hypotension, tachycardia, and acute kidney injury. Echocardiogram showed left ventricular dysfunction with a left ventricular ejection fraction (LVEF) of 45% and moderate pericardial effusion. Early signs of cardiac tamponade were noted, specifically the absence of respiratory variation in the right ventricle and left ventricle collapse. Emergent pericardiocentesis was performed, and hemorrhagic pericardial fluid was aspirated. Fluid analysis revealed high levels of LDH (5000 U/L), polymorphonuclear leukocytosis, and acid-fast bacilli that were visualized on microscopy, which led to the diagnosis of pericardial tuberculosis. A CT of the abdomen showed hepatosplenomegaly and polyserositis. Empirically, antitubercular therapy consisting of isoniazid, rifampin, pyrazinamide, and ethambutol was administered for 2 months and isoniazid along with rifampicin was given for the next 4 months. Serial echocardiograms in the following months showed an improvement in LVEF (55%) and decreased effusion. However, during this treatment period, due to frequent episodes of pneumonia, the evaluation of immunodeficiency disorders was performed and revealed low levels of IgG (4.741 g/L), IgA (0.238 g/L), and IgM (0.098 g/L). He was diagnosed with common variable immunodeficiency disease and received intravenous immunoglobulin therapy. Conclusion: This report emphasizes the timely identification of cardiac tamponade and the effective management of EPTB through a shorter-than-recommended course of antitubercular therapy, resulting in the alleviation of symptoms and better overall health outcomes.
- 15 January 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-6
Open AccessShorter antitubercular therapy for extrapulmonary tuberculosis - a case report
Introduction: Extrapulmonary tuberculosis (EPTB) adds to India’s significant economic burden, with pericardial effusion being a potentially fatal complication. This case report highlights the need for early diagnosis and the feasibility of shorter-duration treatment for EPTB in developing countries. Presentation: This case report describes a 19-year-old male from Southeast Asia who had a history of bronchiectasis involving the left lower lobe and the right middle lobe, which was cystic in nature, as well as multiple episodes of non-tuberculous pneumonia. Currently, he presented with fever, hypotension, tachycardia, and acute kidney injury. Echocardiogram showed left ventricular dysfunction with a left ventricular ejection fraction (LVEF) of 45% and moderate pericardial effusion. Early signs of cardiac tamponade were noted, specifically the absence of respiratory variation in the right ventricle and left ventricle collapse. Emergent pericardiocentesis was performed, and hemorrhagic pericardial fluid was aspirated. Fluid analysis revealed high levels of LDH (5000 U/L), polymorphonuclear leukocytosis, and acid-fast bacilli that were visualized on microscopy, which led to the diagnosis of pericardial tuberculosis. A CT of the abdomen showed hepatosplenomegaly and polyserositis. Empirically, antitubercular therapy consisting of isoniazid, rifampin, pyrazinamide, and ethambutol was administered for 2 months and isoniazid along with rifampicin was given for the next 4 months. Serial echocardiograms in the following months showed an improvement in LVEF (55%) and decreased effusion. However, during this treatment period, due to frequent episodes of pneumonia, the evaluation of immunodeficiency disorders was performed and revealed low levels of IgG (4.741 g/L), IgA (0.238 g/L), and IgM (0.098 g/L). He was diagnosed with common variable immunodeficiency disease and received intravenous immunoglobulin therapy. Conclusion: This report emphasizes the timely identification of cardiac tamponade and the effective management of EPTB through a shorter-than-recommended course of antitubercular therapy, resulting in the alleviation of symptoms and better overall health outcomes.
- Open Access
- 23 December 2023
- Published by Elsevier in Journal of Cardiology Cases
- Vol. 29 (4) , 161-164
Paradoxical septic embolism in an Ebstein's anomaly patient leading to brain abscess: A case report
- 23 December 2023
- Published by Elsevier in Journal of Cardiology Cases
- Vol. 29 (4) , 161-164
Open AccessParadoxical septic embolism in an Ebstein's anomaly patient leading to brain abscess: A case report
- Open Access
- 1 March 2022
- Published by Medknow in Indian Dermatology Online Journal
- Vol. 13 (2) , 244-247
Pyoderma Gangrenosum with Splenic Abscess- A Rare Association
Pyoderma gangrenosum is a rare, chronic neutrophilic dermatosis of unknown etiology. The classical clinical feature of pyoderma gangrenosum is a pustule or plaque that rapidly progresses to a painful, necrotic ulcer with undermined violaceous margins. Pyoderma gangrenosum may be associated with underlying inflammatory bowel diseases, hematological malignancies, or rheumatologic disorders in 50–70% of the cases. The visceral involvement by pyoderma gangrenosum is rare. Sterile neutrophilic infiltrates in organs other than the skin are uncommon systemic manifestations of neutrophilic dermatoses, but have occasionally been reported. We report a case of a 38-year-old female with pyoderma gangrenosum and visceral involvement manifesting as splenic abscess.
- 1 March 2022
- Published by Medknow in Indian Dermatology Online Journal
- Vol. 13 (2) , 244-247
Open AccessPyoderma Gangrenosum with Splenic Abscess- A Rare Association
Pyoderma gangrenosum is a rare, chronic neutrophilic dermatosis of unknown etiology. The classical clinical feature of pyoderma gangrenosum is a pustule or plaque that rapidly progresses to a painful, necrotic ulcer with undermined violaceous margins. Pyoderma gangrenosum may be associated with underlying inflammatory bowel diseases, hematological malignancies, or rheumatologic disorders in 50–70% of the cases. The visceral involvement by pyoderma gangrenosum is rare. Sterile neutrophilic infiltrates in organs other than the skin are uncommon systemic manifestations of neutrophilic dermatoses, but have occasionally been reported. We report a case of a 38-year-old female with pyoderma gangrenosum and visceral involvement manifesting as splenic abscess.